ArticleFrontiers in microbiology2019
Genetic Features of
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Genomic Insights Into Carbapenem-Resistant Klebsiella pneumoniae in Pediatric Bloodstream Infections in Zhejiang, China (2019-2024).Journal of clinical laboratory analysis · 2026Article
- Genomic analysis of ST117, 155, 1011, 167, 744, and 17391 in poultry-associated multidrug resistant Escherichia coli isolates from India.Scientific reports · 2026Article
- The Gut Microbiome and Colistin Resistance: A Hidden Driver of Antimicrobial Failure.International journal of molecular sciences · 2025Review
- Genotypic characterization of extended-spectrum beta-lactamase-producingMicrobiology spectrum · 2025Article
- One Health at Risk: Plasmid-Mediated Spread ofAntibiotics (Basel, Switzerland) · 2025Review
- The First Report ofMicroorganisms · 2024Article
- Prevalence and Transmission of Extended-Spectrum Cephalosporin (ESC) Resistance Genes inAntibiotics (Basel, Switzerland) · 2023Article
- First Report and Characterization of theMicroorganisms · 2023Article
- Mobile Colistin Resistance (Antibiotics (Basel, Switzerland) · 2023Review
- First Known Report ofInternational journal of environmental research and public health · 2023Article
- Whole-Genome Sequencing-Based Resistome Analysis of Nosocomial Multidrug-Resistant Non-Fermenting Gram-Negative Pathogens from the Balkans.Microorganisms · 2023Review
- The Clash of the Titans: COVID-19, Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2023Article
- Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2022Article
- Worldwide Prevalence ofPathogens (Basel, Switzerland) · 2022Review
- Epidemiological Prevalence of Phenotypical Resistances and Mobilised Colistin Resistance in Avian Commensal and PathogenicAntibiotics (Basel, Switzerland) · 2022Article
- F Plasmid Lineages in Escherichia coli ST95: Implications for Host Range, Antibiotic Resistance, and Zoonoses.mSystems · 2022Article
- Molecular Detection of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2022Article
- Carbapenemase- and Colistin ResistantInfection and drug resistance · 2022Article
- Spread of theFrontiers in microbiology · 2022Article
- Colistin ResistantVeterinary sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colistin is a last resort antibiotic used for the treatment of human infections associated with carbapenemase-producing Enterobacteriales. Here, we evaluated the occurrence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.